People

Phrontline Biopharma-affiliated co-author of the AACR 2026 research abstract on TJ106, an investigational HER2-targeting antibody-drug conjugate with two cytotoxic payloads. The company’s December 2023 profile identified Hu as Head of Biology with experience in antibody drug discovery and oncology research.